Abstract
Thymic epithelial tumors (TETs) are rare thoracic malignancies with a favorable prognosis when complete surgical resection can be achieved. Therapeutic options for advanced, irresectable, or recurrent disease are limited and currently, a therapeutic standard treatment beyond platinum-based chemotherapy is undefined. Immune checkpoint inhibitors are effective against TETs, however their use is associated with a serious risk of immune-mediated toxicity. In this article, we highlight new insights regarding markers of predictive value for both treatment efficacy and risk of adverse effects in immune checkpoint inhibitor treatment for thymic epithelial tumors.
Reference55 articles.
1. Epidemiology of thymoma;Rich;J. Thorac. Dis.,2020
2. Thymic epithelial tumours: A population-based study of the incidence, diagnostic procedures and therapy;Blaauwgeers;Eur. J. Cancer,2008
3. ITMIG classification of mediastinal compartments and multidisciplinary approach to mediastinal masses;Carter;Radiographics,2017
4. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?;Marx;J. Thorac. Oncol.,2021
5. Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline;Falkson;J. Thorac. Oncol.,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献